Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mydriasis Clear all
Completed Not applicable Interventional

Study on Effective Mydriasis in Premature Infants

NCT01054027
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
1% phenylephrine and 0.2% cyclopentolate
Drug
Lead sponsor
Georgetown University
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751631
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), Tropicamide 1% ophthalmic solution (TR), Phenylephrine 2.5% ophthalmic solution (PE)
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

NCT04024891
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
4
States / cities
Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 2, 2026, 6:01 PM EDT
Not yet recruiting Phase 4 Interventional

Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients

NCT06366217
View directory record Official record
Conditions
Dilation, Pupil Reaction Absent
Interventions
MydCombi Device, MydCombi Drug
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 6:01 PM EDT
Terminated Not applicable Interventional Results available

Optimal Method for Mydriasis in Cataract Surgery

NCT02909140
View directory record Official record
Conditions
Cataract
Interventions
Topical phenylephrine 2.5%, Topical cyclopentolate 1%, Intracameral Lidocaine 1%, Intracameral 0.2- 0.3ml of epinephrine 1:10,000
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

NCT04620213
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
12
States / cities
Newport Beach, California • San Diego, California • Longwood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 0.4% Ketorolac and Vitreoretinal Surgery

NCT00576329
View directory record Official record
Conditions
Surgery
Interventions
Ketorolac
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 2, 2026, 6:01 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pupillary Dilation Reflex in Healthy Volunteers

NCT07746167
View directory record Official record
Conditions
Healthy Participants
Interventions
No intervention (observational study)
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"

NCT01860534
View directory record Official record
Conditions
Light Sensitivity
Interventions
eye covers
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil

NCT02946125
View directory record Official record
Conditions
Mydriasis
Interventions
MDD-administered EYN-1601, Phenylephrine 2.5% Eyedrop, Phenylephrine 10% Eyedrop
Combination Product · Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

NCT03139708
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Alphagan, Phenylephrine, Tropicamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751098
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

NCT05134974
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation

NCT06217796
View directory record Official record
Conditions
Mydriasis
Interventions
MydCombi
Combination Product
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

Pupil Dilation for Treatment of IFIS

NCT03760185
View directory record Official record
Conditions
Intraoperative Floppy Iris Syndrome
Interventions
Brimonidine Tartrate
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Not applicable Interventional Results available

Efficacy of the Nanodropper Device on Pupillary Dilation

NCT05274321
View directory record Official record
Conditions
Dilation
Interventions
Nanodropper, Standard Eye Dropper
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter

NCT06689904
View directory record Official record
Conditions
Medication Delivery, Eye Drop Delivery
Interventions
Nanodropper, Standard eye drop bottle
Device
Lead sponsor
Sutter Health
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 2, 2026, 6:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

NCT00413751
View directory record Official record
Conditions
Healthy
Interventions
Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2006 · Synced Sep 2, 2026, 6:01 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Pupillometry and Locus Coeruleus Activation (PuLCA)

NCT04579653
View directory record Official record
Conditions
Visual Impairment, Ocular Illness
Interventions
transcutaneous electrical nerve stimulation devices
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 2, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

NCT05223478
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Longwood, Florida • Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 2, 2026, 6:01 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Exploration of Pupil Dilation in Horner's Patients Taking Flomax

NCT03615508
View directory record Official record
Conditions
Horner Syndrome
Interventions
10% phenylephrine
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 2, 2026, 6:01 PM EDT
Enrolling by invitation Not applicable Interventional

Pupillary Dilation During Post-Auricular Vagal Nerve Stimulation

NCT05870527
View directory record Official record
Conditions
Hearing Loss
Interventions
Electrical stimulator
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 2, 2026, 6:01 PM EDT